A Turning Point for ME/CFS and Long COVID (2025–2026)

Something big is happening in ME/CFS and long COVID research.

After years of uncertainty, we’re finally seeing real progress. Thanks to major global funding and new technology, researchers are beginning to understand these conditions as part of the same group: post-infectious syndromes.

A large NIH study found that the risk of developing ME/CFS is about 5x higher after COVID, pointing to shared biology like low cellular energy, chronic inflammation, and immune dysfunction.

At the same time, diagnostics are improving fast. AI-based tools and new blood tests can now identify ME/CFS with up to 90–96% accuracy, moving the field closer to objective diagnosis.

On the treatment side, several promising paths are emerging:

• The ØKNING study (Uppsala/Harvard) is testing Mestinon and LDN — results expected soon

• Rapamycin may help by improving how cells recycle and produce energy

• Daratumumab has shown striking effects in a subgroup by targeting harmful autoantibodies

• Other trials are exploring everything from anti-inflammatory drugs to gut-based therapies

Meanwhile, large projects are mapping patients’ biological profiles to enable precision medicine — matching the right treatment to the right person.

2026 may mark the shift from just managing symptoms to actually addressing the underlying biology.

For the first time in a long time, the direction is clear — and the hope is real.